232 related articles for article (PubMed ID: 31669761)
1. Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses.
Musharrafieh R; Ma C; Wang J
Eur J Pharm Sci; 2020 Jan; 141():105124. PubMed ID: 31669761
[TBL] [Abstract][Full Text] [Related]
2. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
Ma C; Zhang J; Wang J
Mol Pharmacol; 2016 Sep; 90(3):188-98. PubMed ID: 27385729
[TBL] [Abstract][Full Text] [Related]
4. 3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
Rey-Carrizo M; Torres E; Ma C; Barniol-Xicota M; Wang J; Wu Y; Naesens L; DeGrado WF; Lamb RA; Pinto LH; Vázquez S
J Med Chem; 2013 Nov; 56(22):9265-74. PubMed ID: 24237039
[TBL] [Abstract][Full Text] [Related]
5. Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.
Musharrafieh R; Ma C; Wang J
Antiviral Res; 2018 May; 153():10-22. PubMed ID: 29518414
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.
Li F; Ma C; Hu Y; Wang Y; Wang J
ACS Infect Dis; 2016 Oct; 2(10):726-733. PubMed ID: 27657178
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus.
Duncan MC; Onguéné PA; Kihara I; Nebangwa DN; Naidu ME; Williams DE; Balgi AD; Andrae-Marobela K; Roberge M; Andersen RJ; Niikura M; Ntie-Kang F; Tietjen I
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599753
[TBL] [Abstract][Full Text] [Related]
8. Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India.
Jacob A; Sood R; Chanu KhV; Bhatia S; Khandia R; Pateriya AK; Nagarajan S; Dimri U; Kulkarni DD
Microb Pathog; 2016 Feb; 91():35-40. PubMed ID: 26639679
[TBL] [Abstract][Full Text] [Related]
9. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.
Musharrafieh R; Lagarias PI; Ma C; Tan GS; Kolocouris A; Wang J
Mol Pharmacol; 2019 Aug; 96(2):148-157. PubMed ID: 31175183
[TBL] [Abstract][Full Text] [Related]
10. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with
Cáceres CJ; Hu Y; Cárdenas-García S; Wu X; Tan H; Carnaccini S; Gay LC; Geiger G; Ma C; Zhang QY; Rajao D; Perez DR; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):1832-1848. PubMed ID: 34427541
[TBL] [Abstract][Full Text] [Related]
11. Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.
Wu Y; Canturk B; Jo H; Ma C; Gianti E; Klein ML; Pinto LH; Lamb RA; Fiorin G; Wang J; DeGrado WF
J Am Chem Soc; 2014 Dec; 136(52):17987-95. PubMed ID: 25470189
[TBL] [Abstract][Full Text] [Related]
12. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening and molecular growth guide the design of inhibitors for the influenza virus drug-resistant mutant M2-V27A/S31N.
Deng C; Wang X; Wang T; Liu W; Yuan X; Huang Y; Cao S
J Biomol Struct Dyn; 2024 Jul; 42(10):5253-5267. PubMed ID: 37424098
[TBL] [Abstract][Full Text] [Related]
14. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.
Balannik V; Wang J; Ohigashi Y; Jing X; Magavern E; Lamb RA; Degrado WF; Pinto LH
Biochemistry; 2009 Dec; 48(50):11872-82. PubMed ID: 19905033
[TBL] [Abstract][Full Text] [Related]
15. Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
Rey-Carrizo M; Barniol-Xicota M; Ma C; Frigolé-Vivas M; Torres E; Naesens L; Llabrés S; Juárez-Jiménez J; Luque FJ; DeGrado WF; Lamb RA; Pinto LH; Vázquez S
J Med Chem; 2014 Jul; 57(13):5738-47. PubMed ID: 24941437
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.
Wang J; Ma C; Wang J; Jo H; Canturk B; Fiorin G; Pinto LH; Lamb RA; Klein ML; DeGrado WF
J Med Chem; 2013 Apr; 56(7):2804-12. PubMed ID: 23437766
[TBL] [Abstract][Full Text] [Related]
17. Isocyanides as Influenza A Virus Subtype H5N1 Wild-Type M2 Channel Inhibitors.
Wu S; Huang J; Gazzarrini S; He S; Chen L; Li J; Xing L; Li C; Chen L; Neochoritis CG; Liao GP; Zhou H; Dömling A; Moroni A; Wang W
ChemMedChem; 2015 Nov; 10(11):1837-45. PubMed ID: 26506405
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.
Ilyushina NA; Bovin NV; Webster RG; Govorkova EA
Antiviral Res; 2006 Jul; 70(3):121-31. PubMed ID: 16516984
[TBL] [Abstract][Full Text] [Related]
19. Divalent copper complexes as influenza A M2 inhibitors.
Gordon NA; McGuire KL; Wallentine SK; Mohl GA; Lynch JD; Harrison RG; Busath DD
Antiviral Res; 2017 Nov; 147():100-106. PubMed ID: 29032206
[TBL] [Abstract][Full Text] [Related]
20. Abuse of amantadine in poultry may be associated with higher fatality rate of H5N1 infections in humans.
Yuan S; Jiang SC; Zhang ZW; Fu YF; Zhu F; Li ZL; Hu J
J Med Virol; 2022 Jun; 94(6):2588-2597. PubMed ID: 35170774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
